Signaling Pathways in Breast Cancer

Dr. Sumel Ashique has been working as an assistant professor at the Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, West Bengal, India. He has 5 years of teaching experience. He has achieved 100+ publications in international and national accredited reputed journals. He has expertise in drug delivery, nanotechnology, and targeted treatment strategies. Recently, he was honored to be in the World’s Top 2% Scientists by prestigious Stanford University, CA, United States, and Elsevier in 2025.Dr. Neeraj Mishra is Professor and Head of the Department of Pharmaceutics at the Amity Institute of Pharmacy, Gwalior. He has over 20 years of teaching and research experience in pharmaceutics, with particular expertise in novel drug delivery systems, localized and targeted drug delivery, and nanocarrier-based therapeutics for disease. His formulations and controlled delivery approaches are aimed at improving therapeutic outcomes. Dr. Mishra has supervised postgraduate and doctoral research scholars, has contributed widely to academic literature through research publications, books, and book chapters with leading international publishers. He has won several awards including Outstanding Scientist Award, and Distinguished Professor Award. He is associated with innovation in pharmaceutical sciences through patented research contributions. Over the course of his career, he has received several academic and scientific recognitions for his contributions to teaching, and research. He has been recognized internationally for his research impact and scholarly contributions.Dr. Farzad Taghizadeh-Hesary is an Assistant Professor of Radiation Oncology at Iran University of Medical Sciences, specializing in oncology, radiobiology, and cancer metabolism. He earned his M.D. in 2015 from IUMS and completed a Radiation Oncology residency at Shahid Beheshti University of Medical Sciences, ranking among the top graduates nationally. His thesis examined late toxicities after IMRT for nasopharyngeal carcinoma, reflecting a commitment to precision radiotherapy.His expertise spans clinical and academic oncology, with a focus on tumor microenvironment and mitochondrial metabolism in cancer. He has published more than 80 peer-reviewed articles and serves on editorial boards including BMC Cancer and PLoS ONE. Awards include the Razi Medical Science Research Prize and the Outstanding Reviewer Award from JCO Clinical Cancer Informatics; Publons Academy ranked him the top global Radiation Oncology reviewer in 2021.His research centers on personalized radiotherapy, cancer immunotherapy, and metabolic interventions targeting mitochondrial dysfunction, advancing translational oncologyDr. Vliora Maria is a Molecular Biologist with extensive background in molecular biology and integrative physiology. She has previously studied mutations of immunoglobulins in Chronic Lymphocytic Leukemia patients, and ALK mutations and downstream signaling in Neuroblastoma. Dr. Vliora has a PhD in Biomedical Research from University of Thessaly, Greece and University of Brescia, Italy. She has worked on the development of biocompatible/biodegradable bioscaffolds for targeting adipose tissue as well as on potential nanomedical treatments for brain tumors as well as blood malignancies. Her research work is now focusing on environmental influences that can affect human health and on the use of novel biodegradable bio-scaffolds for allografting adipose stem cells in humans. She collaborated with reputable organizations (WHO, ILO) on projects aiming to enhance human health and wellbeing. She now works as a Project Manager on EU funded projects.

Select Guide Rating

• 1. Introduction to Breast Cancer and Signaling Pathways2. Emerging Molecular Targets in Breast Cancer Therapy3. Role of Tumor Microenvironment in Breast Cancer Development4. Molecular Subtypes of Breast Cancer and Their Clinical Significance5. Key Signaling Pathways in Breast Cancer Progression6. RNA-Based Therapies: miRNA and siRNA in Breast Cancer Treatment7. Targeting Angiogenesis: VEGF and Its Inhibitors8. Antibody-Drug Conjugates (ADCs) in Breast Cancer Treatment9. Small Molecule Kinase Inhibitors: Current Status and Future Directions10. Nanotechnology and Precision Drug Delivery for Breast Cancer11. MDR and Strategies to Overcome Therapy Failure12. Combination Therapies for Overcoming Resistance in Breast Cancer13. Targeting Autophagy in Overcoming Multidrug Resistance14. Role of Biomarker-Based Therapeutic Approaches15. Role of CRISPR in Triple Negative Breast Cancer16. ERK Signaling and Breast Cancer17. Artificial Intelligence in Breast Cancer Therapy18. Role of Microbiota in Breast Cancer Progression and Therapy19. Heterogeneity and Drug Resistance in Breast Cancer20. Advancement Therapeutic Approaches in Drug Resistance Breast Cancer Management21. Bridging Theory and Practice in Breast Cancer: Case Studies and Clinical Insights22. Challenges and Innovations in Therapeutic Strategies in Treatment of Breast Cancer